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Abstract:  45 
Context. Aldosterone synthesis and cellularity in the human adrenal zona glomerulosa (ZG) is sparse and 46 
patchy, presumed due to salt excess. The frequency of somatic mutations causing aldosterone-producing 47 
adenomas (APA) may be a consequence of protection from cell loss by constitutive aldosterone 48 
production.  49 
Objective. To delineate a process in human ZG which may regulate both aldosterone production and cell 50 
turnover.  51 
Design. Comparison of 20 pairs of ZG and zona fasciculata (ZF) transcriptomes from adrenals adjacent to 52 
an APA (n=13) or a pheochromocytoma (n=7). 53 
Interventions. Over-expression of top ZG gene (LGR5), or stimulation by its ligand (R-spondin-3). 54 
Main Outcome Measures. 1) Transcriptome profile of ZG and ZF; 2) Aldosterone production, cell kinetic 55 
measurements, and Wnt signaling activity of LGR5 transfected or R-spondin-3-stimulated cells.  56 
Results. LGR5 was the top gene up-regulated in ZG (25-fold).  The gene for its cognate ligand R-spondin-57 
3, RSPO3, was 5-fold up-regulated. In total, 18 genes associated with the Wnt pathway were >2-fold up-58 
regulated. ZG selectivity of LGR5, and its absence in most APAs, were confirmed by qPCR and 59 
immunohistochemistry. Both R-spondin-3 stimulation and LGR5 transfection of human adrenal cells 60 
suppressed aldosterone production. There was reduced proliferation and increased apoptosis of transfected 61 
cells, and the non-canonical AP-1/Jun pathway was stimulated more than the canonical Wnt pathway (3-62 
fold vs. 1.3-fold). ZG of adrenal sections stained positive for apoptosis markers.  63 
Conclusion. LGR5 is the most selectively expressed gene in human ZG, and reduces aldosterone 64 
production and cell number. Such conditions may favour cells whose somatic mutation reverses 65 
aldosterone inhibition and cell loss.  66 
67 
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Introduction 68 
Since their discovery by Conn nearly 60 years ago, APAs have been regarded as infrequent ‒ less than 1% 69 
of all hypertension; recent estimates of prevalence, however, have risen to several times this figure (1). 70 
Most APAs, though, are diagnosed too late for complete cure of hypertension (2), and there is a need for 71 
better-tolerated drugs that block the increased aldosterone production. Current treatments either compete 72 
with aldosterone for its receptor, or inhibit the Na+ channel downstream. In addition to limitations of 73 
efficacy or selectivity, such drugs increase aldosterone production (3). Novel drug targets can be identified 74 
by the discovery of either a gene whose gain-of-function mutation increases aldosterone production in 75 
APAs, or pathways coupled to inhibition of aldosterone in the normal adrenal.  76 
 77 
APAs are often a heterogeneous mixture of cells; paradoxically, the cells of classical Conn’s tumours 78 
appear more like cortisol-producing ZF cells than the supposedly aldosterone-producing cells of normal 79 
ZG (4,5). This paradox may be resolved by the frequent finding of small APAs  (often missed on 80 
conventional adrenal imaging) that consist mainly of compact cells, and express genes, such as NPNT 81 
(encoding for nephronectin), not expressed in the ZF of human adrenals (6,7). Exome-sequencing of ten 82 
such ‘ZG-like’ APAs led us to identify somatic mutations in three genes, encoding CaV1.3, Na+, K+-83 
ATPase, and β-catenin (7); no ZG-like APAs have yet been found to have one of the KCNJ5 mutations 84 
common in larger, more ZF-like, APAs (8-11). The small size of many of these ZG-like APAs, sometimes 85 
documented as unchanged in serial CT scans over many years, inferred limited growth before diagnosis. 86 
This observation suggested to us that cells in a ZG-like APA may derive a survival advantage from 87 
constitutive aldosterone production, rather than cell division, thus explaining the frequency of somatic 88 
mutations – 19 different mutations in Cav1.3 alone – which switch on constitutive aldosterone production 89 
(7,11,12).  90 
 91 
In most species, ZG is unusually proliferative for an endocrine tissue, stimulated by the renin-angiotensin 92 
II response to salt depletion; but in typically salt-loaded humans, the reverse appears true (13,14). We 93 
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hypothesized the existence of a local process, in addition to withdrawal of renin, which might suppress ZG 94 
cell steroidogenesis or proliferation when not required. Previous comparisons of human adrenal ZG and 95 
ZF have depended on techniques, such as immunohistochemistry (IHC) and in situ hybridisation that 96 
require investigation of specific candidate molecules (15,16). The striking difference in appearance, 97 
following cresyl violet staining, between lipid-poor and lipid-rich cells of ZG and ZF (6), enabled us to 98 
carry out laser capture microdissection of snap-frozen fresh adrenal sections; and thus whole transcript 99 
expression analysis and profiling of ZG and ZF. The resulting top ZG gene identified, LGR5, is postulated 100 
to be key to this local suppression process of ZG cell activity, highlighting both a possible novel drug 101 
target that can inhibit aldosterone production, and a possible link between the frequency of APAs and 102 
aldosterone secretion. 103 
 104 
Materials and Methods 105 
Study design 106 
To determine genes and pathways regulating aldosterone production, transcriptome profiles of supposedly 107 
aldosterone-producing ZG was compared with its paired cortisol-producing ZF from 20 human adrenals. 108 
The detail method of the microarray assay and clinical demographics of the patients involved is as 109 
described previously (17), and briefly described in Supplementary Methods. Adrenals were collected 110 
within 30 minutes of adrenalectomy (due to an APA or pheochromocytoma) with local ethical approval 111 
and informed consent from the patients. Adrenals immediately underwent collagenase dispersion for 112 
primary cell culture, or were stored at -70ºC for RNA analyses, histology and IHC.  113 
 114 
Comparison of ZG and ZF transcriptome profile led us to hypothesise an important role for LGR5 (the top 115 
ZG gene identified) and the Wnt signaling pathway in the regulation of aldosterone production in the 116 
human adrenal. The hypothesis was tested in the human adrenocortical carcinoma cell line, H295R, and in 117 
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primary human adrenal cell cultures.  The primary outputs of cell culture experiments were aldosterone 118 
secretion into the supernatant of cultures, and qPCR for CYP11B2 expression (encoding for the enzyme 119 
aldosterone synthase).  These were measured in response to key proteins modulating the Wnt signaling 120 
pathway, either administered externally, or by transfection of cDNA constructs.  121 
 122 
Laser capture microdissection (LCM)  123 
LCM was used to obtain samples of ZF and ZG cells from adrenal tissue adjacent to APAs or 124 
pheochromocytomas as previously described (5). For differentiation of ZG from ZF, sections were stained 125 
with cresyl violet using the LCM Staining Kit (AM1935, Ambion). 126 
 127 
Quantification of mRNA expression 128 
Cells were kept in RNAlater and TRIzol (both from Ambion) until extracted for RNA. Total DNA-free 129 
RNA was isolated using the PureLink® RNA Mini Kit with the PureLink® DNase Set (Life 130 
Technologies) according to manufacturer’s instructions. Reverse transcription was performed using the 131 
Reverse Transcriptase System (Promega) with a 1:1 mixture of random hexamer and oligo-dT primers 132 
according to manufacturer’s instructions. mRNA expression of genes of interest was quantified using 133 
TaqMan probes (Applied Biosystems), and CYP11B2 expression was quantified using custom-made 134 
TaqMan probes that had been validated for specificity (20). The housekeeping 18S rRNA (Applied 135 
Biosystems) was used for normalization. 136 
 137 
Immunohistochemistry (IHC) 138 
IHC was performed on formalin-fixed, paraffin-embedded human adrenal sections (4 µm) using a 139 
chromogen based detection system, 3,3′-diaminobenzidine (DAB). Commercial antibodies to LGR5 140 
(#TA503316, Origene; 1:300 dilution), β-catenin (#610154, BD Transduction Laboratories; 1:300 141 
dilution), LEF1 (#ab53293, Abcam plc; 1:100), c-JUN (#ab32137, Abcam; 1:250 dilution) and phospho-c-142 
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JUN (#SC-822, Santa Cruz Biotechnology; 1:100) were used on slides selected from patient adrenals 143 
included in the microarray. Negative controls, in which primary and then secondary antibodies were 144 
omitted were used, and resulted in absence of staining. Slides were counter-stained with haematoxylin 145 
solution (Harris modified; Sigma-Aldrich). To negate cross reactivity of LGR5 antibody with LGR5’s 146 
close homologs, LGR4 and LGR6, additional anti-LGR5 antibodies (Novus Biologicals NBP128904, 147 
Abcam ab75732) that binds to epitopes which through Blast analysis (NCBI) aligned specifically to LGR5 148 
but differs in sequence to LGR4 and LGR6, were also tested in serial human adrenal sections. 149 
 150 
Apoptosis was examined using TUNEL staining visualized by a rhodamine-labeled anti-digoxigenin 151 
antibody (#11093088910, Roche Diagnostics Corp) and proliferation was captured using an anti-Ki67 152 
antigen (#M7240, Dako; 1: 400 dilution) according to manufacturer’s instructions. Images were captured 153 
using a standard bright-field microscope, a U-TV1-X digital camera and CellD software (Olympus). 154 
 155 
Cell culture experiments 156 
H295R human adrenocortical carcinoma cells and primary adrenocortical cells were cultured in 157 
DMEM/Nutrient F-12 Ham supplemented with 10% FCS, 100 U of penicillin, 0.1 mg/ml streptomycin, 158 
0.4 mM L-glutamine and insulin-transferrin–sodium selenite medium (ITS) at 37 °C in 5% CO2 as 159 
previously described (17). Cells were transfected with vector controls pCMV6-AC-GFP (Origene) or 160 
pcDNA3.1/His A (Invitrogen) and GFP tagged LGR5 (Origene; 600ng/ul). Transfections were carried out 161 
using Cell Line Nucleofector Kit R (VACA-1001; Lonza) according to the manufacturers’ guidelines. Cell 162 
fate assays were performed in LGR5 transfected cells as described in Supplementary Methods. Cells 163 
were silenced using either ON-TARGETplus Non-Targeting siRNA as control or SMART pool: ON-164 
TARGET plus LGR5 siRNA (Dharmacon; 50nM). Transfected cells were plated into 24-well plates 165 
(100,000 cells per well) in 0.25 ml of growth medium. After 24h of transfection, H295R cells were serum 166 
deprived in unsupplemented medium for 24h, further drug treatments were carried out with 8hr incubation 167 
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from this point. Recombinant hR-spondin-3 (Sino Biological Inc and R&D Systems) was used where 168 
specified at 100 nM. Supernatants for aldosterone concentration measurement were collected after 169 
respective 8h treatments, and cells were harvested for analysis of mRNA. Aldosterone concentrations 170 
were determined by a commercially available 125I radioimmunoassay (Diagnostic Products Corp) as 171 
detailed in Supplementary Methods. 172 
 173 
Wnt signaling pathway activity assays 174 
TCF/LEF response was measured using Cignal TCF/LEF Reporter (luc) Kit (SABiosciences). AP1/JUN 175 
pathway response was measured using a construct created by cloning an oligo containing 7 copies of the 176 
AP1 binding element (TGACTAA) into a luciferase construct pGL4.10 (luc2) (Promega) at its KpnI and 177 
XhoI sites. pRL-TK was used for normalisation (Promega). NFAT response was also measured using a 178 
luciferase reporter construct (plasmid #10959, Addgene). 179 
 180 
Plasmids modulating Wnt signaling pathway were used as comparator to show effect on aldosterone of 181 
activation or suppression of the canonical pathway. To activate the pathway, pcDNA3 ΔN47 β-catenin 182 
was used; and to suppress the pathway, pcDNA/Myc ΔN TCF4 (both from Addgene). Where indicated the 183 
vector control, pcDNA3.1-V5His (Invitrogen) was used. To measure luciferase (and renilla for 184 
normalization) Dual-Glo® Luciferase Assay System (Promega) was used according to the manufacturer’s 185 
protocol. The selective porcine inhibitor, LGK-974 (1µM, Selleck Chemicals) (21), and the selective c-186 
Jun N-terminal kinase (JNK) inhibitor, JNK-IN-8 (1µM, Selleck Chemicals)(22), were used to analyse the 187 
effect of blocking respectively, all Wnts secretion or just the non-canonical Wnt signaling pathway.  188 
 189 
Statistical analysis 190 
Unless otherwise stated, results are expressed as mean values ± SEM. Statistical analysis was performed 191 
using the Student's unpaired t test or analysis of variance on standard statistical software.  192 
9 
 
 193 
Results  194 
LGR5 and several other genes associated with the Wnt signaling pathway are selectively and abundantly 195 
expressed in human adrenal ZG 196 
Transcriptome analysis by Affymetrix microarray identified 213 genes, which were between 2- and 25-197 
fold more abundant in human adrenal ZG than their paired ZF (Supplemental Fig. 1). The top ‘hit’ was 198 
LGR5 (P=1.6x10-23; Fig. 1a and Table 1)(17), which in several tissues is recognized as a stem-cell 199 
marker (23,24). The possibility of LGR5 playing a key role in ZG was supported by finding that the 200 
expression of the gene for its cognate ligand R-spondin-3, RSPO3, was also up-regulated in ZG by 5-fold 201 
(P=3x10-11). Overall, 18 of the 213 ‘ZG-genes’ encode previously identified proteins associated with the 202 
Wnt signaling pathway (Table 1). By contrast, only 1 of 117 ‘ZF-genes’ (those >2-fold more abundant in 203 
ZF than ZG) encodes for a known protein from this Wnt signaling pathway.  204 
 205 
The expression of LGR5 in ZG was confirmed by qPCR as 306-fold up-regulated compared to ZF (n=18, 206 
P=3.01x10-9). By contrast, in 12 APAs qPCR found expression of LGR5 to be only 1.7% of that in the 207 
adjacent ZG.  mRNA results were confirmed at protein level through IHC using three commercial antisera 208 
raised against differing epitopes (Supplemental Fig. 2a). IHC of key Wnt genes (β-catenin, the central 209 
signaling molecule of the canonical Wnt pathway; LEF1, the nuclear transcription factor activated by β-210 
catenin; c-Jun, the target of the polarity non-canonical Wnt pathways; and phospho-c-Jun) in serial human 211 
adrenal sections showed ZG-selective distribution with co-localization of LGR5 (Fig. 1b and 212 
Supplemental Fig. 2b). In addition to the ZG-selective staining, some adrenals showed radial streaking 213 
into ZF for LGR5 in serial sections, reminiscent of the pattern previously associated with centripetal 214 
migration of ZG cells (Supplemental Fig. 2a) (25,26). Staining of the positive control, small intestine 215 
supported the specificity of LGR5 staining in the adrenals (Supplemental Fig. 2c). Most β-catenin 216 
staining was membranous or cytoplasmic, with a few cells showing the nuclear staining induced by 217 
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canonical Wnt activation (Fig. 1b). Microarray analysis detected neither of the canonical Wnt ligands, 218 
Wnt1 or Wnt3a, as up-regulated in ZG, and their absolute expression in both adrenal zones were low. 219 
 220 
Transfection and treatment of LGR5 and R-spondin-3 show reduction of aldosterone secretion in H295R 221 
cells and primary adrenals 222 
Functional studies, over-expression and silencing of LGR5 and treatment with its cognate ligand R-223 
spondin-3, were performed on either the immortalised human adrenocortical H295R cell line or normal 224 
primary adrenal cells cultured from adrenalectomized adrenals of patients diagnosed with either primary 225 
hyperaldosteronism or pheochromocytoma.  226 
 227 
In both cell line and primary cultures, 100 nM of R-spondin-3 treatment caused a reduction in aldosterone 228 
secretion and CYP11B2 expression (Fig. 2a-d). LGR5 transfection similarly reduced aldosterone 229 
production (Fig. 2e, f). Conversely, silencing of LGR5 caused an increase in aldosterone production and 230 
CYP11B2 transcription (Fig. 2g, h). Some of the inhibition by R-spondin-3 and LGR5 appeared due to 231 
reduction in cell number as seen on protein assay. However, even after protein correction, there was a 232 
reduction in aldosterone secretion, which was most marked for LGR5-transfected cells exposed to R-233 
Spondin-3 (56±5%, P=0.002 Fig. 2i). 234 
 235 
LGR5 transfection in H295R cells shows reduction of cells 236 
We consistently noted a qualitative reduction in cell number and adhesion following LGR5 transfection or 237 
R-spondin-3 stimulation. Kinetic live-cell imaging of LGR5 transfected cells directly quantified a 43±11% 238 
reduction in the proliferation of H295R cells (P=1.5x10-5) (Fig. 3a), seen also in a cell viability assay 239 
(Supplemental Fig. 3). These observations led us to investigate indices of proliferation and apoptosis in 240 
sections of human adrenal cortex, and in LGR5 transfected H295R cells. In other species, the accepted 241 
model of adrenocortical cell fate has been of a unitary progenitor cell in the capsule that migrates 242 
centripetally through ZG and ZF to zona reticularis (ZR), where it undergoes apoptosis (27,28). In the 243 
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absence of aldosterone production – e.g. in the CYP11B2-/- mouse – the processes of migration and 244 
apoptosis are accelerated (29). By contrast, in human adrenal we found that the main site of apoptosis is 245 
ZG, as seen on both TUNEL and cleaved caspase 3 staining (Fig. 3b and Supplemental Fig. 4). Staining 246 
of H295R cells with Annexin V and separation by flow cytometry quantified higher apoptosis in LGR5-247 
transfected cells compared to vector controls (54±3 % vs. 34±3 %; Fig. 3c). 248 
 249 
LGR5 activates AP1/Jun non-canonical Wnt pathway 250 
Previous studies have shown that canonical Wnt activation increases proliferation and aldosterone 251 
production (15,30). We hypothesized that the inhibition of aldosterone and net cell loss is due to LGR5 252 
inhibition of the canonical Wnt activation (31), though there have been previously postulated non-253 
canonical Wnt effects in human adrenal (32). In order to determine which is the more likely mechanism, 254 
we co-transfected H295R cells with LGR5 or a luciferase reporter with a promoter recognition site for 255 
either TCF/LEF – the canonical Wnt transcription factors, or one of the non-canonical Wnt targets, AP-256 
1/Jun or NFAT (Fig. 4 and Supplemental Fig. 5). In addition, we also investigated the effect on 257 
aldosterone production of a constitutively active or dominant negative canonical Wnt pathway through 258 
transfection of a constitutively active β-catenin (ΔN47 β-catenin) or dominant negative TCF (ΔN TCF4); 259 
and using small molecule inhibitors, we interrogated non-selective inhibition of Wnt signaling pathways 260 
(through inhibition of the Wnt chaperone porcupine) and selective inhibition of the non-canonical Wnt 261 
signaling pathway (through inhibition of JNK).  262 
 263 
H295R cells, whose S45P mutant β-catenin is constitutively active, had the expected high basal levels of 264 
TCF/LEF activity, with only slight further activation on the addition of the ΔN47 β-catenin construct (Fig. 265 
4b). On the other hand, the ΔN TCF4 construct markedly reduced both TCF/LEF activity and aldosterone 266 
production (Fig. 4b, c). In contrast, transfection of LGR5 caused a slight increase in TCF/LEF activity 267 
while decreasing aldosterone secretion (Fig. 4b, c). Supporting a predominant action of LGR5 on a non-268 
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canonical Wnt pathway (Fig. 4d), LGR5 transfection increased AP-1/Jun activity by almost 3-fold and the 269 
non-canonical selective JNK inhibitor, JNK-IN-8, ameliorated this increase (Fig. 4e). JNK-IN-8 270 
inhibition, however, was insufficient to reverse LGR5’s mediated suppression of aldosterone secretion 271 
(Fig. 4f), suggesting that AP1/Jun is not the only non-canonical pathway involved. The consequences of 272 
blocking Wnt signaling with the non-selective porcupine inhibitor, LGK974, had a similar inhibitory 273 
effect on aldosterone production as was seen with the TCF ΔN construct (Fig. 4e, f). LGR5 had no 274 
significant influence on the NFAT reporter construct (Fig. S7) 275 
 276 
Discussion  277 
We found the most-up-regulated gene in normal human ZG, compared to its adjacent ZF, to be LGR5, and 278 
that its transfection into human adrenocortical cells results in inhibition of aldosterone production, 279 
reduction in cell number, and activation of a non-canonical Wnt signaling pathway postulated as the 280 
mediator of the LGR5 response.  281 
 282 
Wnt signaling has well-documented roles in normal adrenal development, adrenocortical tumours, and 283 
H295R cells (30,32,33). However, no definite physiological role has been ascribed to Wnt in the 284 
regulation of aldosterone, especially in humans (34). The dominant inhibitory role of Wnt that we have 285 
found in human ZG helps to explain the lack of similarity between our microarray findings from the 286 
current study and those reported from adrenal tissues in which aldosterone production is stimulated. For 287 
example, none of the genes associated with the Wnt signaling pathway that were up-regulated in normal 288 
human ZG were up-regulated in our previous microarray analyses of APAs – one comparing APAs with 289 
adjacent adrenal, and the other comparing ZG-like APAs with more ZF-like APAs (6,7). Further, LGR5 290 
was almost absent from adjacent APAs in the present study. Finally, only one of our 18 Wnt related genes 291 
(GPC3) was similarly up-regulated in a microarray comparison of CYP11B2 positive cells in rat ZG with 292 
adjacent ZF (35). We believe that the key difference between human ZG on the one hand, and either 293 
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adjacent APAs or rat ZG on the other, is that the dominant signaling pathway activated in the latter are 294 
those which stimulate aldosterone production, whilst the reverse appears true of human ZG.  295 
 296 
We found that, unlike its reported effects in other tissues (23,24), LGR5 in human adrenal cells stimulates 297 
predominantly non-canonical pathways. The AP-1/Jun pathway, which was markedly stimulated by LGR5 298 
transfection of H295R cells, influences cell migration (36). Its activation is also a measure for Rho/ROCK 299 
regulation of both migration and polar cell polarity (see Fig 3d). The latter has not been studied in human 300 
ZG cells, but could be key to the formation of glomerular structure and tight junctions, as known genes 301 
associated with these structures (TJP1 and CLDN1) were among our ZG-selective genes (Supplemental 302 
Fig. S1). Our models of migration or adhesion did not detect an effect of LGR5 (Supplemental Fig. S6), 303 
but probably do not exclude their occurrence in the intact human adrenal. Intact adrenocortical structure 304 
was recently shown to be essential for generation of the voltage oscillations that regulate aldosterone 305 
secretion (37,38). We have not yet established which non-canonical Wnt pathway may be responsible for 306 
inhibition by LGR5 of aldosterone production, since the AP1/Jun inhibitor, JNK-IN-8, had little impact on 307 
the inhibition. 308 
 309 
Our study of ZG genes was prompted by the frequency of somatic mutations leading to common, small 310 
APAs. If aldosterone is required for ZG cell survival, as implied by CYP11B2-/- mice (29), cells that 311 
mutate to protect aldosterone production will have a selective advantage. Most cells in human ZG do not 312 
express CYP11B2 (39). The sparseness of CYP11B2 in ZG is a general phenomenon whether adjacent to 313 
an APA or to a pheochromocytoma (39,40). The most likely explanation of this down-regulation of 314 
CYP11B2 is a physiological response to high salt intake. If physiological inhibition of aldosterone 315 
production has the same consequences as genetic deletion, as is suggested by our apoptosis data (Fig. 3), 316 
then constitutive activation of aldosterone production following somatic mutations would confer a local 317 
selection advantage to mutated cells. Moreover, since the fate of ZG cells on centripetal migration is to 318 
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proliferate and then disappear (26), the survival advantage to ZG cells may derive from entering synthetic 319 
rather than proliferative mode, providing an explanation as to why ZG-like APAs are often small. 320 
 321 
Few completely normal adrenals are removed at surgery. We therefore restricted our choice to those 322 
adjacent to either an APA or pheochromocytoma, the commonest indications for adrenalectomy in our 323 
hospital. These tumours have opposite effects on sodium balance, and future analyses will consider 324 
differences in expression between the adrenal adjacent to the two tumour types. While, however, a 325 
limitation of our study design is the use of adrenals adjacent to a tumour, which may differ from 326 
completely normal adrenals, there was no difference in expression of LGR5 between these two groups of 327 
patients. It seems unlikely therefore that its abundance is due to the tumours. The immortalised adrenal 328 
cell line, H295R, is also not a perfect model for native ZG cells (41). Although primary adrenal cells are 329 
less easy to transfect in culture than H295R cells, we have supported our findings in the latter where 330 
possible using primary adrenal cells. The assumption taken is that whilst the ZG cells are a minority of the 331 
mixture of ZG, ZF, and ZR cells, only ZG cells contribute to the measurements of aldosterone production. 332 
 333 
Our discovery suggests a hypothetical translational consequence, arising from evidence that the survival 334 
of ZG cells is dependent upon production of aldosterone (29). Current drug treatments for 335 
hyperaldosteronism antagonise aldosterone response, but increase plasma aldosterone levels (3).  Selective 336 
inhibition of aldosterone production has been problematic because of the 95% homology of CYP11B1 337 
(cortisol synthase enzyme) with CYP11B2. But the discovery of adrenally expressed genes whose 338 
mutation activates aldosterone production, and of adrenal pathways linked to reduced aldosterone 339 
secretion, provides novel targets, with potential for clinical development. 340 
 341 
Chronic human diseases are often attributed to maladaptation when scarcity is replaced by plenty. We 342 
speculate that inhibition of aldosterone production by a R-spondin-3-LGR5-non-canonical Wnt signaling 343 
pathway creates a mechanism which is an appropriate response to excess salt, but could paradoxically 344 
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create a survival advantage for cells with somatic mutations causing autonomous aldosterone production. 345 
Identification of this pathway may now provide novel targets for prevention and treatment of 346 
hyperaldosteronism. 347 
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Table 1: Wnt genes with > 2-fold up-regulation in ZG compared to ZF, ranked in order of fold-483 
change (ZG vs. ZF) 484 
Rank Gene name Symbol  P-Value Fold-Change   
1 Leucine-rich repeat-containing G protein-coupled receptor 5  LGR5 1.6 x 10-23 25.0 
9 Secreted frizzled-related protein 4  SFRP4 2.3 x 10-10 8.7 
17 Lymphoid enhancer-binding factor 1  LEF1 4.3 x 10-15 5.9 
19 Cadherin 12, type 2 (N-cadherin 2) CDH12 4.4 x 10-10 5.8 
27 R-spondin 3 homolog (Xenopus laevis) RSPO3 3.3 x 10-11 5.3 
44 FBJ murine osteosarcoma viral oncogene homolog B  FOSB 5.7 x 10-6 3.8 
53 Frizzled-related protein  FRZB 2.4 x 10-8 3.5 
76 Glypican 3  GPC3 1.7 x 10-6 3.1 
89 Transcription factor 21  TCF21 2.4 x 10-5 2.9 
90 Jun B proto-oncogene  JUNB 5.6 x 10-6 2.9 
92 Claudin 1  CLDN1 2.3 x 10-10 2.8 
98 FBJ murine osteosarcoma viral oncogene homolog FOS 9.6 x 10-5 2.8 
105 Frizzled homolog 6 (Drosophila)  FZD6 9.4 x 10-11 2.7 
157 Wingless-type MMTV integration site family, member 4 WNT4 3.2 x 10-8 2.2 
179 Matrix metallopeptidase 2 MMP2 3.5 x 10-6 2.1 
183 Dickkopf homolog 3 (Xenopus laevis) DKK3 4.7 x 10-10 2.1 
206 Low density lipoprotein receptor-related protein 1B LRP1B 3.5 x 10-6 2.0 
209 CD44 molecule (Indian blood group) CD44 6.6 x 10-8 2.0 
*Wnt genes were identified using the list provided at http://www.stanford.edu/group/nusselab/cgi-bin/wnt/ 485 
or http://www.rndsystems.com/molecule_group.aspx?g=484&r=2, or due to the attachment to the GO 486 
term GO:0016055.  487 
 488 
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Fig. 1. Wnt related genes show selective expression in the ZG of human adrenal 489 
 490 
491 
a 
b 
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(a) Heatmap of 37 genes (shown on the vertical axis) which are > 5-fold differentially expressed in ZG 492 
and ZF. Genes previously associated with the Wnt signaling pathway are highlighted in red. On the 493 
horizontal axis, each pairs of ZG and ZF from the 20 adrenals are anonymized and numbered. Probe set 494 
and detailed microarray information are available from the NCBI Gene Expression Omnibus (GEO) under 495 
accession GSE64957.	  496 
(b) IHC localisation of LGR5 and downstream Wnt signaling proteins in the ZG; from the canonical β-497 
catenin pathway‒ β-catenin and LEF1, and from the non-canonical AP1/JUN pathway‒ c-JUN and p-c-498 
JUN. IHC was performed on formalin-fixed, paraffin-embedded human adrenal sections (4 µm) using a 499 
chromogen based detection system (DAB) which results in a positive brown staining. Interestingly, β-500 
catenin staining was mostly membranous or cytoplasmic (rather than nuclear staining as highlighted by 501 
the arrows) indicating limited canonical Wnt activation. Pictures are representative of 6 normal adrenal 502 
sections that were used in our microarray study; 4 from primary hyperaldosteronism patients and 2 from 503 
pheochromocytoma patients. Scale bar = 500µm (low power) and 100µm (high power). 504 
C: Capsule. ZF, F: Zona fasciculata. ZG, G: Zona glomerulosa.  505 
506 
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Fig. 2. LGR5 and its cognate ligand R-spondin-3 inhibit aldosterone production  507 
 508 
 509 
     i 510 
 511 
 512 
 513 
 514 
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R-spondin-3 inhibition of (a) aldosterone secretion (n=12) and (b) CYP11B2 transcription (n=3) by 515 
H295R cells; and (c) aldosterone secretion (n=7) and (d) CYP11B2 transcription (n=3) by normal human 516 
primary adrenal cells from patients with primary hyperaldosteronism. H295R and human primary adrenal 517 
cells were serum deprived in unsupplemented medium for 24h before exposed to vehicle control or R-518 
spondin-3 as specified. Supernatants for aldosterone concentration measurement were collected after 8h 519 
incubation with drug, and cells were harvested for analysis of CYP11B2 mRNA. 520 
LGR5 transfection of H295R cells, showing (e) inhibition of aldosterone secretion (n=17) after 48h of 521 
transfection and (f) inhibition of CYP11B2 transcription (n=3). pCMV6-AC-GFP was used as vector 522 
control (Vector). Silencing of LGR5 in H295R cells (siLGR5) after 48h, showing (g) stimulation of 523 
aldosterone (n=7), and (h) increased CYP11B2 transcription (n=3). ON-TARGET plus Non-Targeting 524 
siRNA (Non Targeting) transfected cells were used as experimental control.  525 
(i) Additive effect of R-spondin-3 treatment on aldosterone production of LGR5 transfected H295R cells 526 
(n=8). H295R cells were transfected with vector controls pCMV6-AC-GFP or GFP-tagged LGR5 527 
(Origene; 600ng/ul). After 24h of transfection, H295R cells were serum deprived in unsupplemented 528 
medium for 24h, and further R-spondin-3 treatments were carried out with 8h incubation from this point.  529 
Results are expressed in mean ±S.E.M. P-values show significance between treatments and baseline 530 
control using student t test. *, P<0.05. **, P<0.01. ***, P<0.001 531 
 532 
 533 
534 
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Fig. 3. LGR5 reduces human adrenocortical cell proliferation and increases apoptosis 535 
 536 
 537 
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(a) Kinetic live-cell imaging compared LGR5 and vector transfected H295R cells. n=6, P=1.5x10-5 using 538 
student t test.  539 
(b) Human adrenal section showing staining for TUNEL (apoptosis marker, dark purple) and cleaved 540 
caspase 3 (apoptosis marker, brown) in the ZG (as arrowed). Pictures are representative of 6 normal 541 
adrenal sections that were used in our microarray study; from 4 primary hyperaldosteronism patients and 2 542 
pheochromocytoma patients. ZG: zona glomerulosa. ZF: zona fasciculata. ZR: zona reticularis. Scale bar= 543 
500um (low power) and 50um (high power).  544 
(c) GFP-tagged LGR5 transfected H295R cells undergoing apoptosis were Annexin V stained for flow 545 
cytometry quantification. In the overlay, the blue line denotes the number of H295R cells stained with 546 
Annexin V that were transfected with vector control while the red line denotes the same for LGR5 547 
transfected cells. n=3, P=0.009 using student t test.  548 
549 
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Fig. 4. Dominant action of LGR5 on the non-canonical (AP1 /Jun) pathway  550 
a         b 551 
 552 
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(a) Schema showing genes expressed in the human adrenal from the canonical Wnt signaling pathway. 554 
Numbers (in red) show site of action of Wnt related proteins, which were either used or measured in the 555 
experiment (1:R-spondin-3, 2:LGR5, 3:β-catenin, 4:TCF). (b) Canonical Wnt signaling activity of H295R 556 
cells transfected with control vectors (Vector), LGR5, ΔN47 β-catenin (encoding a constitutively active β-557 
catenin) or ΔN TCF4 (encoding a dominant negative TCF) were measured through co-transfection with a 558 
luciferase construct that had a TCF/LEF-responsive promoter (Cignal TCF/LEF Reporter (luc) Kit, 559 
SABiosciences). (c) Aldosterone secretion during the same experiments (n=5).  560 
 (d) Schema showing Wnt genes expressed in the adrenal from the non-Canonical Wnt signaling pathway. 561 
Numbers (in red) show site of action of Wnt related proteins, which were either used or measured in the 562 
experiment (1:LGR5, 2:JNK, 3:AP1, 4: JUN). (e) AP-1/Jun non-canonical Wnt activity measured in the 563 
presence of LGK974 (porcupine inhibitor) and JNK-IN-8 (JNK inhibitor) (both 1µM). (f) Aldosterone 564 
secretion during the same experiment (n=4).  565 
Results are expressed in mean ±S.E.M and P-values show significance between treatments and baseline 566 
control.*, P<0.05. **, P<0.01. ***, P<0.001 using student t test.   567 
 568 
